Aprea Therapeutics Inc (APRE)

Jun 04, 2026

Aprea Expands Cancer Trial After Early Tumor Responses - MyChesCo

Jun 04, 2026

Jun 01, 2026

Aprea's WEE1 Drug Shows Early Promise in Hard-to-Treat Cancers - BriefGlance

Jun 01, 2026

Jun 01, 2026

H.C. Wainwright Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $1.2 - Moomoo

Jun 01, 2026

Jun 01, 2026

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors - The Manila Times

Jun 01, 2026

Jun 01, 2026

Cancer trial drug APR-1051 posts partial responses at ASCO 2026 - Stock Titan

Jun 01, 2026

May 28, 2026

Aprea Therapeutics (APRE) Edges Higher Amid Light Trading; Key Resistance at $0.99 in FocusOBV Divergence - The Legal Advocate

May 28, 2026

May 28, 2026

Aprea Therapeutics (APRE) Edges Higher Amid Low Volume TradingATR Stop - The Legal Advocate

May 28, 2026

May 25, 2026

Aprea Therapeutics (APRE) upgraded to buy: Here's what you should know - MSN

May 25, 2026

May 22, 2026

Aprea Expands Cancer Trial After $30 Million Financing - MyChesCo

May 22, 2026

May 21, 2026

Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know - sharewise.com

May 21, 2026

May 20, 2026

This Aprea Therapeutics analyst begins coverage on a bullish note; here are top 3 initiations for Thursday - MSN

May 20, 2026

May 15, 2026

Vestal Point reports 9.9% stake in Aprea Therapeutics (NASDAQ: APRE) - Stock Titan

May 15, 2026

May 15, 2026

Aprea Therapeuticsfiles for resale of up to 5.5 million shares by selling stockholdersSEC filing - marketscreener.com

May 15, 2026

May 15, 2026

[424B7] Aprea Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(7) - Stock Titan

May 15, 2026

May 15, 2026

Aprea Therapeutics 1Q Research and Development Expenses $1.6M >APRE - Moomoo

May 15, 2026

May 14, 2026

Wedbush Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Cuts Target Price to $6 - Moomoo

May 14, 2026

May 14, 2026

Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo

May 14, 2026

May 14, 2026

Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target - TipRanks

May 14, 2026

May 14, 2026

Press Release: Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Moomoo

May 14, 2026

May 14, 2026

Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating - Moomoo

May 14, 2026

May 14, 2026

Aprea Therapeutics, Inc. Q1 2026 10-Q Report – Financials, Risk Factors, and Forward-Looking Statements - Minichart

May 14, 2026

May 13, 2026

Aprea Therapeutics Releases Q1 2026 Financial Results - AlphaStreet

May 13, 2026

May 13, 2026

Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress - TipRanks

May 13, 2026

May 13, 2026

Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher - ChartMill

May 13, 2026

May 13, 2026

Aprea Therapeutics (NASDAQ: APRE) trims Q1 loss and raises over $34M to extend cash runway - Stock Titan

May 13, 2026

May 13, 2026

APREA THERAPEUTICS ($APRE) Releases Q1 2026 Earnings - Quiver Quantitative

May 13, 2026

May 13, 2026

Aprea Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(0.22) — 10-Q Summary - TradingView

May 13, 2026

May 13, 2026

Aprea Therapeutics Reports Q1 2026 Results: $30M Financing Boosts APR-1051 Clinical Progress and Extends Cash Runway to 2028 - Minichart

May 13, 2026

May 13, 2026

Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 13, 2026

May 13, 2026

Aprea Therapeutics Closes Oversubscribed $30 Million Private Placement to Advance APR-1051 Development and Reports Positive Early Data from Phase 1 Trial - Quiver Quantitative

May 13, 2026

May 13, 2026

Aprea Therapeutics Q1 net loss narrows as R&D expenses fall - TradingView

May 13, 2026

May 13, 2026

8-K: Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Updatemoomoo - Moomoo

May 13, 2026

May 13, 2026

Aprea (NASDAQ: APRE) extends cash runway and reports Q1 2026 results - Stock Titan

May 13, 2026

May 13, 2026

Early tumor responses and $30M cash boost for Aprea cancer drug - Stock Titan

May 13, 2026

May 12, 2026

A Breakout Year for WEE1? Oppenheimer Sees 6x Upside in This Under-the-Radar Biotech - Barchart.com

May 12, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

May 11, 2026

APRE (Aprea) beats Q4 earnings by 20%, but shares fall 2.3% amid growth concerns.Earnings Growth Forecast - newsline.com

May 11, 2026

May 09, 2026

APRE (Aprea) Q4 earnings beat expectations with smaller loss than estimated, shares climb 5.66%.Put/Call Ratio - Newser

May 09, 2026

May 08, 2026

Aprea Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView

May 08, 2026

May 07, 2026

This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga

May 07, 2026

May 07, 2026

Oppenheimer Initiates Aprea Therapeutics at Outperform With $5 Price Target - marketscreener.com

May 07, 2026

May 07, 2026

Oppenheimer initiates Aprea stock with Outperform on WEE1 inhibitor potential - Investing.com Nigeria

May 07, 2026

May 07, 2026

Oppenheimer initiates Aprea stock with Outperform on WEE1 inhibitor potential By Investing.com - Investing.com South Africa

May 07, 2026